Re­genxBio ral­ly fades fast af­ter biotech re­ports set­backs, hos­pi­tal­iza­tion in gene ther­a­py study

Re­genxBio $RGNX has some ex­plain­ing to do to­day.

In its quar­ter­ly re­port the gene ther­a­py com­pa­ny re­port­ed that it ex­pe­ri­enced sev­er­al set­backs dur­ing its Phase …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.